base-metals-investing Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
base-metals-investing Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
base-metals-investing Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
base-metals-investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
base-metals-investing BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
base-metals-investing Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
base-metals-investing Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
base-metals-investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - October 02, 2025
base-metals-investing Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
base-metals-investing Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
base-metals-investing Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - September 03, 2025
base-metals-investing Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
base-metals-investing Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award
American Pacific Mails Meeting Materials for Annual General and Special Meeting in Connection with Previously Announced Plan of Arrangement with ICG Silver & Gold Ltd.
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
